BCM
BCRX icon

BlueCrest Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

BlueCrest Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-15,478
Closed -$89K – 1515
2018
Q2 		$89K Buy
+15,478
New +$85.2K ﹤0.01% 1403
2017
Q4 		– Sell
-82,262
Closed -$431K – 835
2017
Q3 		$431K Buy
+82,262
New +$421K 0.02% 553

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's BCRX Position: Q3 2018 in Review

BlueCrest Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2018, closing a stake of 15,478 shares — an estimated $89K sold.

BlueCrest Capital Management first reported a position in BCRX in Q3 2017 and held it in 2 quarters. The position peaked at $431K in Q3 2017. 116 funds tracked by Wall St. Rank hold BCRX as of Q3 2018.

  • BlueCrest Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 15,478 BioCryst Pharmaceuticals shares in Q3 2018, an estimated $89K.
  • BlueCrest Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • BlueCrest Capital Management's BioCryst Pharmaceuticals position peaked at $431K in Q3 2017.
  • 116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2018.

Based on BlueCrest Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.